AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
GRAIL Inc.
Video analysis: GRAL
All videosNo video analysis for this stock yet. Request one from our team.
News: GRAL
Concurrent Investment Advisors LLC Grows Position in GRAIL, Inc. $GRAL
Concurrent Investment Advisors LLC raised its stake in GRAIL, Inc. (NASDAQ: GRAL) by 65.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 30,253 shares of the company's stock after acquiring an additional 12,002 shares during the quarter. Concurrent Investment
Grail CFO Aaron Freidin Sells 7,900 Shares for $672,000
The transaction was valued at approximately $672,000. The shares traded represented 3% of the direct equity stake held by the CFO prior to the filing.
Grail Stock Jumps in August as FDA Schedules a Key Meeting for its Galleri Cancer Test
FDA approval is crucial for Galleri's adoption by insurers. The company received some good news from the FDA, and a pivotal meeting is coming up for Grail's Galleri test.
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SUNNYVALE, Calif., Sept. 3, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 55,867 shares of GRAIL's common stock to 59 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL.
GRAIL to Present at Morgan Stanley's 24th Annual Global Healthcare Conference
MENLO PARK, Calif., Aug. 31, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Monday, Sep. 14 at 11:30 a.m.
GRAIL Highlights Galleri Growth Ahead of Key FDA Advisory Meeting
GRAIL NASDAQ: GRAL Chief Financial Officer Aaron Freidin said the company's Galleri multi-cancer early detection test recorded strong first-half growth as it expanded distribution through digital health platforms, employers and physician offices.
Bank of America Corp DE Purchases 205,611 Shares of GRAIL, Inc. $GRAL
Bank of America Corp DE raised its holdings in shares of GRAIL, Inc. (NASDAQ: GRAL) by 29.0% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 914,114 shares of the company's stock after purchasing an additional 205,611 shares
GRAIL: Looking Beyond The NHS-Galleri Headline
GRAIL faces a binary FDA approval event for Galleri, with significant stock movement expected based on the outcome. Despite disappointing NHS-Galleri trial results, I believe the true value of the test would have been apparent with a longer monitoring period. While GRAL has a solid cash position, commercialization delays could see the company having to raise a large amount of capital on unfavorable terms.
Similar companies
-
Dyne Therapeutics, Inc.
DYN
·
NASDAQ
Compare
-
Ultragenyx Pharmaceutical Inc.
RARE
·
NASDAQ
Compare
-
Apogee Therapeutics, Inc.
APGE
·
NASDAQ
Compare
-
Xenon Pharmaceuticals Inc.
XENE
·
NASDAQ
Compare
-
Envista Holdings Corp
NVST
·
New York Stock Exchange
Compare
-
Ascentage Pharma Group International
AAPG
·
NASDAQ
Compare